IHC
Leica Biosystems, Molecular Instruments Partner on Tissue Research Products
The companies will combine their in situ hybridization imaging and immunohistochemistry and immunofluorescence technologies to enable the simultaneous detection of RNA and protein targets on the same tissue.
HER2 Biomarker Evolving as Enhertu Shows Activity in Breast Cancers With Ultralow Expression
Premium
The new HER2-low category is exposing the limitations of IHC testing, challenging pathologists, and has oncologists revisiting patients' old test results.
Microenvironments Give Clues to Distinct Immunotherapy Responses in Brain Metastases, Glioblastomas
Investigators found microenvironment differences in checkpoint blockade immunotherapy-treated cases involving brain metastases versus recurrent glioblastoma.
Companies that built their business in tissue and blood-based DNA analyses are now exploring imaging technologies across a variety of fronts.
End-Stage Ovarian Cancer Marked by Rampant Treatment Resistance, Multiple Clones
By profiling multiple tumors per patient, researchers found pronounced polyclonal disease and diverse resistance mechanisms in end-stage high-grade serous ovarian carcinoma.